Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07219212 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase 1 study of Squamous Cell Carcinoma of Head and Neck, sponsored by Johnson & Johnson Enterprise Innovation.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
11
Study locations

NCT07219212 is a Phase 1 study of Squamous Cell Carcinoma of Head and Neck that is actively recruiting participants, run by Johnson & Johnson Enterprise Innovation. The registered enrollment target is 30 participants, below the 170-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (82% lower). The trial reports 11 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07219212, a Phase 1 study of Squamous Cell Carcinoma of Head and Neck, is actively recruiting participants, sponsored by Johnson & Johnson Enterprise Innovation.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
11
Study locations

Study Summary

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).

Conditions Studied

Squamous Cell Carcinoma of Head and Neck

Interventions

  • DRUG Cisplatin
  • RADIATION Intensity Modulated Radiation Therapy (IMRT)
  • DRUG JNJ-90301900

Study Locations (11)

Other

  • Hopital De La Cavale Blanche - Brest
  • Hopital La Timone - Marseille
  • Centre Henri Becquerel - Rouen
  • Gustave Roussy - Villejuif
  • Aichi Cancer Center - Nagoya
  • Tokyo Medical University Hospital - Tokyo

Florida

  • Mayo Clinic - Jacksonville
  • Moffit Cancer center - Tampa

California

  • City of Hope - Duarte

Georgia

  • Emory University - Atlanta

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-01-26
Est. Completion 2028-07-14
Phase Phase 1

Sponsor

Johnson & Johnson Enterprise Innovation

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07219212

The ClinicalTrials.gov registry entry for NCT07219212 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (82% lower). The listed sponsor is Johnson & Johnson Enterprise Innovation, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.

NCT07219212 reports 11 study locations spanning 5 distinct geographic areas - top geographies include Other, Florida, California.

Frequently Asked Questions

What is clinical trial NCT07219212 about?

NCT07219212 is a clinical study titled "A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma". This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a ty...

What is the current status of trial NCT07219212?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-01-26. Estimated completion is 2028-07-14.

What conditions does trial NCT07219212 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck.

What interventions are being tested in trial NCT07219212?

The interventions under investigation include: Cisplatin (DRUG), Intensity Modulated Radiation Therapy (IMRT) (RADIATION), JNJ-90301900 (DRUG).

Who is sponsoring clinical trial NCT07219212?

This trial is sponsored by Johnson & Johnson Enterprise Innovation, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07219212 being conducted?

This trial has 11 study locations across California, Florida, Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Cell Carcinoma of Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Squamous Cell Carcinoma of Head and Neck

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.